GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (NAS:CLVR) » Definitions » Debt-to-EBITDA

Clever Leaves Holdings (Clever Leaves Holdings) Debt-to-EBITDA : -0.11 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clever Leaves Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Clever Leaves Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.20 Mil. Clever Leaves Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-18.36 Mil. Clever Leaves Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Clever Leaves Holdings's Debt-to-EBITDA or its related term are showing as below:

CLVR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.9   Med: -0.73   Max: -0.1
Current: -0.12

During the past 5 years, the highest Debt-to-EBITDA Ratio of Clever Leaves Holdings was -0.10. The lowest was -1.90. And the median was -0.73.

CLVR's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs CLVR: -0.12

Clever Leaves Holdings Debt-to-EBITDA Historical Data

The historical data trend for Clever Leaves Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clever Leaves Holdings Debt-to-EBITDA Chart

Clever Leaves Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.81 -1.90 -0.73 -0.10 -0.12

Clever Leaves Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.19 -0.23 -0.09 -0.11

Competitive Comparison of Clever Leaves Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clever Leaves Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's Debt-to-EBITDA falls into.



Clever Leaves Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clever Leaves Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.884 + 1.203) / -16.835
=-0.12

Clever Leaves Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.884 + 1.203) / -18.364
=-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Clever Leaves Holdings  (NAS:CLVR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Clever Leaves Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
Executives
Andres Fajardo director, officer: President CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches officer: Chief Regulatory Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii officer: Chief Financial Officer 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien director ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke director C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin officer: General Counsel C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler director, officer: Chief Executive Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze 10 percent owner C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse director CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges director ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc 10 percent owner 800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey officer: Interim CFO CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017